Kodiak Sciences’ drug candidate KSI-301 improved vision, anatomy or both in eight of nine patients with severe diabetic macular edema in a phase 1a trial, according to a release.
Patients were administered a single injection of KSI-301, an investigational anti-VEGF antibody biopolymer conjugate.
Pooled data from all responders at three dose levels showed median improvement of nine eye chart letters and median OCT improvement of 121 microns at 12 weeks from baseline, according to the release.
“We are very encouraged by the depth and durability of treatment responses. This study of KSI-301 was designed as a first-in-human, single-dose safety study and has exceeded our expectations from the standpoints of bioactivity and durability,” Kodiak Chief Medical Officer and Chief Development Officer Jason Ehrlich, MD, PhD, said.
The company plans a multiple-dose phase 1b study of the drug looking at its broader potential in retinal vascular diseases, including wet age-related macular degeneration and retinal vein occlusion, as well as DME.